DE602004004571D1 - Abhängigkeit des symptomfreien Überlebens 5-FU behandelter Darmkrebspatienten vom Verhältnis der mRNA-Expressionshöhe aus Thymidinphosphorylase und Dihydropyrimidindehydrogenase - Google Patents

Abhängigkeit des symptomfreien Überlebens 5-FU behandelter Darmkrebspatienten vom Verhältnis der mRNA-Expressionshöhe aus Thymidinphosphorylase und Dihydropyrimidindehydrogenase

Info

Publication number
DE602004004571D1
DE602004004571D1 DE602004004571T DE602004004571T DE602004004571D1 DE 602004004571 D1 DE602004004571 D1 DE 602004004571D1 DE 602004004571 T DE602004004571 T DE 602004004571T DE 602004004571 T DE602004004571 T DE 602004004571T DE 602004004571 D1 DE602004004571 D1 DE 602004004571D1
Authority
DE
Germany
Prior art keywords
mrna expression
ratio
symptom
dependence
expression levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004004571T
Other languages
English (en)
Other versions
DE602004004571T2 (de
Inventor
Verena Dr Lutz
Friedmann Dr Krause
Manuela Dr Poignee
Thomas Dr Walter
Baerbel Prof Dr Porstmann
Martin Prof Dr Werner
Silke Dr Lassmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of DE602004004571D1 publication Critical patent/DE602004004571D1/de
Application granted granted Critical
Publication of DE602004004571T2 publication Critical patent/DE602004004571T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602004004571T 2003-08-28 2004-08-25 Abhängigkeit des symptomfreien Überlebens 5-FU behandelter Darmkrebspatienten vom Verhältnis der mRNA-Expressionshöhe aus Thymidinphosphorylase und Dihydropyrimidindehydrogenase Active DE602004004571T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03018783 2003-08-28
EP03018783 2003-08-28

Publications (2)

Publication Number Publication Date
DE602004004571D1 true DE602004004571D1 (de) 2007-03-22
DE602004004571T2 DE602004004571T2 (de) 2007-11-08

Family

ID=34259138

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004004571T Active DE602004004571T2 (de) 2003-08-28 2004-08-25 Abhängigkeit des symptomfreien Überlebens 5-FU behandelter Darmkrebspatienten vom Verhältnis der mRNA-Expressionshöhe aus Thymidinphosphorylase und Dihydropyrimidindehydrogenase

Country Status (7)

Country Link
US (1) US20050100936A1 (de)
EP (1) EP1510588B1 (de)
JP (1) JP4032047B2 (de)
AT (1) ATE353107T1 (de)
CA (1) CA2479446C (de)
DE (1) DE602004004571T2 (de)
ES (1) ES2279266T3 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE477339T1 (de) * 2005-05-31 2010-08-15 Dako Denmark As Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung
DE102006037158A1 (de) * 2006-08-02 2008-02-14 Bioxsys Gmbh Verfahren zur Feststellung der Sensitivität von Tumoren gegenüber Capecitabin und Testkit
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
EP2495568B1 (de) * 2009-10-30 2018-08-22 Keio University Verfahren zur bestimmung der empfindlichkeit für ein antikrebsmittel
WO2011052749A1 (ja) * 2009-10-30 2011-05-05 学校法人慶應義塾 抗がん剤の感受性の判定方法
US20130095473A1 (en) * 2010-06-14 2013-04-18 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
ES2393984B1 (es) * 2011-02-24 2013-11-21 Servicio Andaluz De Salud Método de obtención de datos útiles para evaluar la respuesta al tratamiento con 5-fluorouracilo (5-FU)
EP3067698A1 (de) 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Pd-ecgf als biomarker für krebs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1302026B1 (it) * 1997-08-22 2000-07-20 Hoffmann La Roche Materiali immunologici e metodi per la rivelazione di diidropirimidinadeidrogenasi.
US7005278B2 (en) * 2001-03-02 2006-02-28 Danenberg Kathleen D Method of determining dihydropyrimidine dehydrogenase gene expression

Also Published As

Publication number Publication date
ATE353107T1 (de) 2007-02-15
JP4032047B2 (ja) 2008-01-16
EP1510588B1 (de) 2007-01-31
EP1510588A1 (de) 2005-03-02
CA2479446C (en) 2013-05-07
DE602004004571T2 (de) 2007-11-08
JP2005073698A (ja) 2005-03-24
ES2279266T3 (es) 2007-08-16
CA2479446A1 (en) 2005-02-28
US20050100936A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE602004021838D1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
WO2003035904A3 (en) Methods and compositions to evaluate antibody treatment response
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE553378T1 (de) Screening und behandlungsverfahren zur vorbeugung von frühgeburten
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
BR0205135A (pt) Uso cosmético e uso de uma associação de pelo menos um ativo hidrófilo sensìvel à oxidação estabilizado por pelo menos um polìmero ou copolìmero de n-vinilimidazol, processo cosmético e de tratamento cosmético
DE602004004571D1 (de) Abhängigkeit des symptomfreien Überlebens 5-FU behandelter Darmkrebspatienten vom Verhältnis der mRNA-Expressionshöhe aus Thymidinphosphorylase und Dihydropyrimidindehydrogenase
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
DK1394272T3 (da) Fremgangsmåde til påvisning af ki-ras-mutationer
ATE275411T1 (de) Verwendung von phyllanthus zur behandlung von chronisch entzündlichen und fibrotischen prozessen
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE454476T1 (de) 3'-modifizierte oligonukleotide mit pseudoisocytosin-nukleobasenderivaten sowie deren anwendungen als primer oder sonden
WO2005018535A3 (en) Compositions and methods for treatment of severe acute respiratory syndrome (sars)
NO20053903D0 (no) Nukleotidlipidesterderivater.
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2006013561A3 (en) Compositions and methods for diagnosing and treating post traumatic stress disorder
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
WO2005005661A3 (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets
WO2005060960A3 (en) Use of histamine to treat bone disease
EE200200087A (et) Kompositsioon hepatotsellulaarse kartsinoomi raviks
WO2006053014A3 (en) Selective inhibition of rock1 in cardiac therapy
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts

Legal Events

Date Code Title Description
8364 No opposition during term of opposition